PERRIGO Co plc (PRGO): Results of Operations and Financial Condition
PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S. store-brand OTC and key European brands • Streamlined
How this was made
The 30-second read
Why it matters
The disclosure updates traders on quarterly demand softness, pricing and volume/mix, gross margin drivers (under absorption, mix, tariffs recovery), and segment operating income declines, while reaffirming full-year 2026 outlook with expected sequential improvement.
Market read
A company-specific quarterly earnings release with detailed margin and segment drivers plus a reaffirmed outlook, useful for positioning around Core profitability trends.
What to watch
The filing distinguishes All In versus Core reporting and attributes reported EPS strength to the Dermacosmetics sale gain, which can mask underlying Core profitability trends.
Background
Perrigo is executing a “Three-S plan,” streamlining its portfolio and reducing debt, while reporting both All In and Core results that exclude Infant Formula and certain divestitures.
Ticker impact
Perrigo reported 2Q26 results from continuing operations, including Core net sales down 3.1% and Core adjusted EPS down 20.7% year over year.
Near-term bias likely depends on how investors weigh margin compression and Core EPS decline versus the reaffirmed outlook and Dermacosmetics gain.
This is a primary quarterly disclosure with specific P&L and margin drivers (under absorption, mix, tariffs recovery) and a portfolio simplification step, but the outlook is only reaffirmed, not raised.
Market effects
Read-across for consumer self-care and store-brand OTC peers on category softness, pricing decline, and margin pressure from under-absorption.
European brand performance is referenced, but no region-specific guidance changes are quantified.
Limited global spillover beyond consumer staples-style defensives, since the filing is company-specific and outlook is reaffirmed.
Counterpoint
Investors may focus on market share gains and the sequentially stronger second-half framing, treating Core margin compression as temporary under-absorption rather than structural deterioration.
Key entities
- issuerPerrigo Company plc
Subject of the SEC 8-K, reporting 2Q26 continuing operations results and reaffirming full-year 2026 outlook.
- divestitureDermacosmetics business
Sale completed in the quarter, contributing to a gain on sale and simplifying the portfolio.
- strategic reviewInfant Formula and Oral Care businesses
Strategic reviews are ongoing, with Infant Formula net sales growth cited in the quarter.
